默沙东（MRK）今日盘前股价大涨5.35%，引起了市场的广泛关注。
消息面上，默沙东公布了2026年第一季度财务业绩。财报显示，公司第一季度营收同比增长5%至163亿美元，超出市场预期的158亿美元。尽管因收购Cidara Therapeutics相关费用录得季度亏损，但调整后每股亏损为1.28美元，优于分析师预期的1.51美元。
公司核心产品表现强劲，其中重磅抗癌药Keytruda销售额增长12%至80亿美元，超出预期；肺部疾病药物Winrevair销售额飙升88%至5.25亿美元。此外，动物保健业务销售额跃升13%至18亿美元。基于良好的开局，默沙东同时上调了2026年全年业绩指引，增强了投资者信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.